Lean Hogs (LH)

Labcorp Holdings (NYSE:LH) Stock

Labcorp Holdings

Laboratory Corp

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Medicine,Development,Laboratory:,Caucasian,Female,Scientist,Using,Microscope,,Analyzes,Petri

Analyst Color

Earnings

News

Guidance

Health Care

Analyst Ratings

Trading Ideas

General

Laboratory Corporation Of America Holdings

Labcorp&#39;s Q4 EPS of $3.45 topped estimates, with sales rising 9.8% to $3.33 billion. 2025 guidance points to continued growth in diagnostics and biopharma.

Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook

jim_cramer_owen_byrne copy

Long Ideas

Markets

Media

PENN

UBER

Jim Cramer Says Lazard Is &#39;Really Inexpensive,&#39; Recommends Buying This Tech Stock

Medicaid.Healthcare

Government

Regulations

Politics

ALHC

CLOV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Trump&#39;s second term could bring significant changes to U.S. healthcare, with cuts to ACA subsidies and potential Medicare privatization.

Donald Trump&#39;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare

Labcorp Holdings Inc

Leo Holdings Corp II Warrants (07/01/2028)

Lucira Health Inc Ordinary Shares

LIC HSG FIN S/GDR 144A by Lic Housing Finance Ltd.

LIGHTHOUSE GLOGAL HLDGS by Lighthouse Global Holdings Inc.

Lighthouse Global Holdings Inc

LEHMAN BRO HLDC/T 6.00% M by Lehman Brothers Holdings, Inc.

Lehman Brothers Holdings Capital Trust V

LEADER HILL CORP by Leader Hill Corp.

LIFEHOUSE RETIREMENT PPTY by LifeHouse Retirement Properties, Inc.

LIGHTSTONE VALUE REIT by Lightstone Value Plus REIT Inc.

Lightstone Value Plus REIT I Inc

LIANHUA SUPERMKT HLDGS CO by Lianhua Supermarket Holdings Ltd.

Lianhua Supermarket Holdings Co Ltd

LIANHUA SPRMKT UNSP/ADR by Lianhua Supermarket Holdings Ltd.

L3Harris Technologies Inc

Lhyfe SA

Piper Sandler analyst David Westenberg maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Neutral and raises the price target from $240 to $260.

Price Target

Piper Sandler Maintains Neutral on Labcorp Holdings, Raises Price Target to $260

Barclays analyst Jack Meehan maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and lowers the price target from $271 to $260.

Barclays Maintains Equal-Weight on Labcorp Holdings, Lowers Price Target to $260

Jefferies analyst Tycho Peterson maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and raises the price target from $275 to $290.

Jefferies Maintains Buy on Labcorp Holdings, Raises Price Target to $290

Thursday,&nbsp;Laboratory Corp&nbsp;(NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.39</a>.
Sales increased 9.8% year-over-year to $3.33 billion, almost in line with the consensus of $3.31 billion.
The increase was due to organic revenue growth of 5.4%, acquisitions, net of divestitures of 4%, and foreign&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43523377/labcorp-announces-2024-fourth-quarter-and-full-year-results" rel="noreferrer noopener">currency translation of 0.3%</a>.
&#8220;In 2024, Labcorp delivered exceptional results driven by both organic and inorganic growth,&#8221; said&nbsp;Adam Schechter, chairman and CEO of Labcorp&#8230;Additionally, we strengthened our presence in key high growth areas including oncology, women&#8217;s health, neurology and autoimmune disease. In 2025, we are positioned to deliver strong growth and margin expansion across both Diagnostics Laboratories and Biopharma Laboratory Services&#8230;&#8221;
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
Adjusted operating income for the quarter was&nbsp;$423.2&nbsp;million, or 12.7% of revenue, compared to&nbsp;$394.9 million, or 13%, in the fourth quarter.
William Blair analyst Andrew F. Brackmann writes, &#8220;We continue to believe the underlying business at Labcorp is on solid footing, as the diagnostics segment benefits from favorable macro tailwinds and the BLS segment sees solid growth in central labs (albeit decelerating off tough comps) and early development returns to growth.&#8221;
This positions the stock well for 2025, with stable guidance and potential for gains if the company&#8217;s momentum continues.
William Blair reiterates the Outperform rating.
Guidance: LabCorp expects 2025 adjusted EPS of 15.60-$16.40 versus the consensus of $16.0. It expects 2025 sales of $13.9 billion-$14.1 billion versus consensus Of $13.8 billion.
The guidance includes 2025 Diagnostics Laboratories sales growth of 6.5%- 7.7% and Biopharma Laboratory Services&nbsp;sales growth of 3.0%- 5.0%.
Price Action:&nbsp;Laboratory stock is down 0.92% at $247.68 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43523277/volkswagen-unveils-plan-for-e20000-entry-level-electric-car" target="_blank" rel="noreferrer noopener">Volkswagen Unveils Plan For Entry-Level, $20K ID Electric Car: Details</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Labcorp shares are trading lower. The company reported Q4 financial results.

Guidance for 2025
The following guidance assumes foreign exchange rates effective as of December&nbsp;31, 2024, for the full year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5" rowspan="1">(Dollars in billions, except per share data)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Results</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Labcorp Enterprise (1)(2)</td>
<td colspan="1" rowspan="1">$13.01</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.7&nbsp;%</td>
<td colspan="1" rowspan="1">8.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diagnostics Laboratories (3)</td>
<td colspan="1" rowspan="1">$10.14</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.5&nbsp;%</td>
<td colspan="1" rowspan="1">7.7&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Biopharma Laboratory Services (4)</td>
<td colspan="1" rowspan="1">$2.92</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3.0&nbsp;%</td>
<td colspan="1" rowspan="1">5.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$14.57</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$15.60</td>
<td colspan="1" rowspan="1">$16.40</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow</td>
<td colspan="1" rowspan="1">$1.10</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.10</td>
<td colspan="1" rowspan="1">$1.25</td>
</tr>
</tbody>
</table>
</figure>

Labcorp Expects 2025 Sales Of $13.88B-$14.05B Versus Consensus Of $13.79B, and Adjusted EPS Of $15.60-$16.40 Versus Consensus Of $16.02

Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) reported quarterly earnings of $3.45 per share which beat the analyst consensus estimate of $3.39 by 1.77 percent. This is a 4.55 percent increase over earnings of $3.30 per share from the same period last year. The company reported quarterly sales of $3.33 billion which beat the analyst consensus estimate of $3.31 billion by 0.63 percent. This is a 9.76 percent increase over sales of $3.03 billion the same period last year.

Laboratory Corp Q4 2024 Adj EPS $3.45 Beats $3.39 Estimate, Sales $3.33B Beat $3.31B Estimate

AAMI

AFRM

AGCO

AMRK

AMZN

APTV

BILL

CCEC

CIGI

CLFD

CLSK

CRNC

CTLP

DOCS

EMBC

ENTG

EXPE

EXPO

FARM

FBIN

FTNT

GOOS

GPRO

GTES

GTIM

HUBG

IBEX

IDCC

IIIV

ILMN

INTR

KVUE

LADR

LESL

LION

LITE

LIVE

LQDT

LSPD

LTRX

MAGN

MATW

MCFT

MCHP

MKTX

MPWR

MSGE

MTSI

Earnings Scheduled For February 6, 2025

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $273.0, with a high estimate of $286.00 and a low estimate of $265.00. This current average has increased by 3.1% from the previous average price target of $264.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1738620063_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Labcorp Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$271.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$286.00</td>
<td>$293.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$271.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$275.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Labcorp Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Labcorp Holdings's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Labcorp Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>Get to Know Labcorp Holdings Better</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Labcorp Holdings showcased positive performance, achieving a revenue growth rate of 7.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Labcorp Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Labcorp Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.09%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.96%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Labcorp Holdings's debt-to-equity ratio is below the industry average at 0.94, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 6 Analysts Discuss Labcorp Holdings Stock

Barclays analyst Jack Meehan maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and raises the price target from $249 to $271.

Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $271

UBS analyst Kevin Caliendo maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and lowers the price target from $293 to $286.

UBS Maintains Buy on Labcorp Holdings, Lowers Price Target to $286

In the preceding three months, 8 analysts have released ratings for Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $261.62, with a high estimate of $289.00 and a low estimate of $234.00. This upward trend is evident, with the current average reflecting a 2.77% increase from the previous average price target of $254.57.
<img src="https://www.benzinga.com/files/images/story/2025/1736287234_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Labcorp Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$271.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$275.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$249.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$289.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$234.00</td>
<td>$249.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Labcorp Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Labcorp Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Labcorp Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>About Labcorp Holdings</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings's Economic Impact: An Analysis</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Labcorp Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.37% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Labcorp Holdings's net margin is impressive, surpassing industry averages. With a net margin of 5.16%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.09%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Labcorp Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.96%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.94.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 8 Analysts Discuss Labcorp Holdings Stock

Evercore ISI Group analyst Elizabeth Anderson upgrades Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) from In-Line to Outperform and raises the price target from $260 to $265.

Upgrades

Evercore ISI Group Upgrades Labcorp Holdings to Outperform, Raises Price Target to $265

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying more Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>).
On Jan. 2, JMP Securities analyst Andrew Boone downgraded Uber from Market Outperform to Market Perform and <a href="https://www.benzinga.com/quote/UBER/analyst-ratings">maintained the price target of $95</a>.
The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) is a buy, Cramer said. &#8220;I think it's time to pick up that utility.&#8221;
On Dec. 6, AES increased its quarterly dividend from 17.25 cents to 17.595 cents per share.
Cramer said he doesn't like PENN Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>).
On Dec. 13, JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $19 to $27.
When asked about Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>), Cramer said, &#8220;It's been very, very tough to own this great steel maker.&#8221;
On Dec. 16, the company provided fourth-quarter guidance, expecting EPS of 55 cents to 65 cents, versus the consensus of 86 cents.
Lazard, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) is &#8220;really inexpensive,&#8221; the &#8220;Mad Money&#8221; host said.
On Dec. 20, Keefe, Bruyette &amp; Woods analyst Aidan Hall downgraded Lazard from Outperform to Market Perform and lowered the price target from $65 to $57.
Cramer recommended to hold on to Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
On Dec. 20, the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
&#8220;I think the stock at 15 times earnings is fine,&#8221; Cramer said when asked about Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>). &#8220;The problem is its healthcare, and people do not like the healthcare stocks.&#8221;
On Dec. 17, Morgan Stanley analyst Ricky Goldwasser maintained Labcorp with an Overweight and raised the price target from $260 to $270.
Price Action:
<ul>
<li>Uber shares gained 4.7% to settle at $63.17 on Thursday.</li>
<li>AES shares rose 1.4% to close at $13.05 during the session.</li>
<li>Penn Entertainment shares fell 2.9% to settle at $19.24.</li>
<li>Lazard shares fell 1.4% to settle at $50.74 on Thursday.</li>
<li>Eli Lilly shares gained 0.8% to $778.07 on Thursday.</li>
<li>Nucor shares fell 1.9% to settle at $114.48 on Thursday.</li>
<li>Labcorp shares fell 0.5% to close at $228.19.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Acuity Brands Stock Ahead Of Q1 Earnings</a></li>
</ul>
Photo: Courtesy of <a href="https://www.flickr.com/photos/ojbyrne/" target="_blank" rel="noreferrer noopener">Owen Byrne</a> on flickr

Jim Cramer Says Lazard Is 'Really Inexpensive,' Recommends Buying This Tech Stock

Morgan Stanley analyst Ricky Goldwasser maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Overweight and raises the price target from $260 to $270.

Morgan Stanley Maintains Overweight on Labcorp Holdings, Raises Price Target to $270

Labcorp Reports Commercial Availability Of Its New H5 Bird Flu Molecular Test To Aid In  Diagnosis Of Human Infection With H5 Bird Flu

B of A Securities analyst Derik De Bruin maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and raises the price target from $262 to $271.

B of A Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $271

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $256.56, a high estimate of $289.00, and a low estimate of $234.00. Witnessing a positive shift, the current average has risen by 1.29% from the previous average price target of $253.29.
<img src="https://www.benzinga.com/files/images/story/2024/1733839301_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Labcorp Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$275.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$249.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$289.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$234.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$235.00</td>
<td>-</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$240.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$282.00</td>
<td>$278.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Labcorp Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Labcorp Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>Get to Know Labcorp Holdings Better</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings's Economic Impact: An Analysis</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Labcorp Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.37% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Labcorp Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.16% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Labcorp Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.09%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Labcorp Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.96%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.94, Labcorp Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Labcorp Holdings's Future

Jefferies analyst Brian Tanquilut assumes Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy rating and announces Price Target of $275.

Initiation

Jefferies Assumes Labcorp Holdings at Buy, Announces Price Target of $275

Labcorp Finalized Its Acquisition Of Select Assets And Molecular Testing Location Of Lab Works, An Accredited Independent Clinical Laboratory Located In Birmingham, Alabama For An Undisclosed Amount

Press Releases

Labcorp Announces 2024 Third Quarter Results

Praia Health Secures Strategic Investment from Labcorp Venture Fund, Announces New Collaboration to Streamline Patient Lab Ordering Experience

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

Outcomes4Me and Labcorp Study Reveals Digital Education Can Increase HER2-low Awareness for Metastatic Breast Cancer Patients

Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order through Physicians

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Labcorp to Announce Fourth Quarter Financial Results on February 6, 2025

Dividends

LABCORP DECLARES QUARTERLY DIVIDEND

Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference

Labcorp Announces 2024 Fourth Quarter and Full Year Results

BGNE

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Labcorp Holdings

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga